DGIdb - MOCETINOSTAT Drug Record

MOCETINOSTAT chembl:CHEMBL272980 Antineoplastic

Alternate Names:

MGCD0103
MOCETINOSTAT
MGCD-0103
chembl:CHEMBL272980
chemidplus:726169-73-9
pubchem.compound:9865515
drugbank:11830

Drug Info:

FDA Approval	not approved
Drug Class	Small molecule
Drug Indications	antineoplastic agent

(3 More Sources)

Publications:

Marson CM et al., 2015, Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit., J Med Chem
Marson CM et al., 2013, Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit., J Med Chem
Khan et al., 2008, Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors., Biochem. J.
Beckers et al., 2007, Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group., Int. J. Cancer
Cruickshank et al., 2017, Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin., Leukemia

MOCETINOSTAT HDAC1

Interaction Score: 0.88

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
26287310 23829483 17455259 17868033

Sources:
DTC TdgClinicalTrial ChemblInteractions GuideToPharmacology TTD
MOCETINOSTAT HDAC3

Interaction Score: 0.82

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Histone deacetylase 3

Direct Interaction? False

PMIDs:
26287310 23829483 17455259

Sources:
DTC TdgClinicalTrial ChemblInteractions GuideToPharmacology
MOCETINOSTAT HDAC11

Interaction Score: 0.79

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name MGCD-0103

Novel drug target Established target

Mechanism of Interaction Histone deacetylase 11

PMIDs:
26287310 23829483

Sources:
DTC TdgClinicalTrial ChemblInteractions
MOCETINOSTAT HDAC2

Interaction Score: 0.78

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name MGCD-0103

Novel drug target Established target

Mechanism of Interaction Histone deacetylase 2 inhibitor

PMIDs:
17868033 26287310 23829483

Sources:
DTC TdgClinicalTrial ChemblInteractions GuideToPharmacology
MOCETINOSTAT HDAC8

Interaction Score: 0.6

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name MGCD-0103

Novel drug target Established target

Mechanism of Interaction Histone deacetylase 8 inhibitor

PMIDs:
26287310 23829483

Sources:
DTC TdgClinicalTrial ChemblInteractions
MOCETINOSTAT HDAC9

Interaction Score: 0.58

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name MGCD-0103

Novel drug target Established target

PMIDs:
26287310 23829483

Sources:
DTC TdgClinicalTrial
MOCETINOSTAT HDAC10

Interaction Score: 0.56

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name MGCD-0103

Novel drug target Established target

PMIDs:
26287310 23829483

Sources:
DTC TdgClinicalTrial
MOCETINOSTAT HDAC7

Interaction Score: 0.53

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name MGCD-0103

Novel drug target Established target

PMIDs:
26287310 23829483

Sources:
DTC TdgClinicalTrial
MOCETINOSTAT HDAC5

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name MGCD-0103

Novel drug target Established target

PMIDs:
26287310 23829483

Sources:
DTC TdgClinicalTrial
MOCETINOSTAT HDAC4

Interaction Score: 0.49

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Established target

Trial Name MGCD-0103

PMIDs:
26287310 23829483

Sources:
DTC TdgClinicalTrial
MOCETINOSTAT HDAC6

Interaction Score: 0.45

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name MGCD-0103

Novel drug target Established target

PMIDs:
26287310 23829483

Sources:
DTC TdgClinicalTrial
MOCETINOSTAT KMT2A

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cytarabine + Mocetinostat

Indication/Tumor Type acute lymphocytic leukemia

Response Type sensitive

PMIDs:
27443263

Sources:
JAX-CKB
MOCETINOSTAT HTT

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD

TdgClinicalTrial: MGCD-0103
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Publications:

DTC: MOCETINOSTAT

Version: 02-September-2020

Alternate Names:

CHEMBL272980 ChEMBL Drug ID

Drug Info:

Publications:

Marson CM et al., 2013, Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit., J Med Chem

Marson CM et al., 2015, Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit., J Med Chem

JAX-CKB: Mocetinostat
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Cruickshank et al., 2017, Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin., Leukemia
TTD: MGCD-0103
- Version: 2020.06.01
Alternate Names:

D00FHR TTD Drug ID

Drug Info:

Publications:
GuideToPharmacology: 178103587
- Version: 29-September-2020
Alternate Names:

MOCETINOSTAT GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL272980
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL272980
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Specific Action of the Ligand	Inhibition
Endogenous Drug?	False
Direct Interaction?	False

Direct Interaction	yes
Mechanism of Interaction	Histone deacetylase 3
Direct Interaction?	False

Trial Name	MGCD-0103
Novel drug target	Established target
Mechanism of Interaction	Histone deacetylase 11

combination therapy	Cytarabine + Mocetinostat
Indication/Tumor Type	acute lymphocytic leukemia
Response Type	sensitive

MOCETINOSTAT Drug Record

MOCETINOSTAT chembl:CHEMBL272980 Antineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

PMIDs: 26287310 23829483 17455259 17868033

Sources: DTC TdgClinicalTrial ChemblInteractions GuideToPharmacology TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Histone deacetylase 3 Direct Interaction? False

PMIDs: 26287310 23829483 17455259

Sources: DTC TdgClinicalTrial ChemblInteractions GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name MGCD-0103 Novel drug target Established target Mechanism of Interaction Histone deacetylase 11

PMIDs: 26287310 23829483

Sources: DTC TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name MGCD-0103 Novel drug target Established target Mechanism of Interaction Histone deacetylase 2 inhibitor

PMIDs: 17868033 26287310 23829483

Sources: DTC TdgClinicalTrial ChemblInteractions GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name MGCD-0103 Novel drug target Established target Mechanism of Interaction Histone deacetylase 8 inhibitor

PMIDs: 26287310 23829483

Sources: DTC TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info: Trial Name MGCD-0103 Novel drug target Established target

PMIDs: 26287310 23829483

Sources: DTC TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: Trial Name MGCD-0103 Novel drug target Established target

PMIDs: 26287310 23829483

Sources: DTC TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: Trial Name MGCD-0103 Novel drug target Established target

PMIDs: 26287310 23829483

Sources: DTC TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: Trial Name MGCD-0103 Novel drug target Established target

PMIDs: 26287310 23829483

Sources: DTC TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: Novel drug target Established target Trial Name MGCD-0103

PMIDs: 26287310 23829483

Sources: DTC TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: Trial Name MGCD-0103 Novel drug target Established target

PMIDs: 26287310 23829483

Sources: DTC TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Cytarabine + Mocetinostat Indication/Tumor Type acute lymphocytic leukemia Response Type sensitive

PMIDs: 27443263

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

TdgClinicalTrial: MGCD-0103

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class Small molecule FDA Approval not approved

Publications:

DTC: MOCETINOSTAT

Alternate Names: CHEMBL272980 ChEMBL Drug ID

Drug Info:

JAX-CKB: Mocetinostat

Alternate Names:

Drug Info:

Publications: Cruickshank et al., 2017, Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin., Leukemia

TTD: MGCD-0103

Alternate Names: D00FHR TTD Drug ID

Drug Info:

Publications:

GuideToPharmacology: 178103587

Alternate Names: MOCETINOSTAT GuideToPharmacology Ligand Name

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL272980

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
26287310 23829483 17455259 17868033

Sources:
DTC TdgClinicalTrial ChemblInteractions GuideToPharmacology TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Histone deacetylase 3

Direct Interaction? False

PMIDs:
26287310 23829483 17455259

Sources:
DTC TdgClinicalTrial ChemblInteractions GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name MGCD-0103

Novel drug target Established target

Mechanism of Interaction Histone deacetylase 11

PMIDs:
26287310 23829483

Sources:
DTC TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name MGCD-0103

Novel drug target Established target

Mechanism of Interaction Histone deacetylase 2 inhibitor

PMIDs:
17868033 26287310 23829483

Sources:
DTC TdgClinicalTrial ChemblInteractions GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name MGCD-0103

Novel drug target Established target

Mechanism of Interaction Histone deacetylase 8 inhibitor

PMIDs:
26287310 23829483

Sources:
DTC TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name MGCD-0103

Novel drug target Established target

PMIDs:
26287310 23829483

Sources:
DTC TdgClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name MGCD-0103

Novel drug target Established target

PMIDs:
26287310 23829483

Sources:
DTC TdgClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name MGCD-0103

Novel drug target Established target

PMIDs:
26287310 23829483

Sources:
DTC TdgClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name MGCD-0103

Novel drug target Established target

PMIDs:
26287310 23829483

Sources:
DTC TdgClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Established target

Trial Name MGCD-0103

PMIDs:
26287310 23829483

Sources:
DTC TdgClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name MGCD-0103

Novel drug target Established target

PMIDs:
26287310 23829483

Sources:
DTC TdgClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cytarabine + Mocetinostat

Indication/Tumor Type acute lymphocytic leukemia

Response Type sensitive

PMIDs:
27443263

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Alternate Names:

CHEMBL272980 ChEMBL Drug ID

Publications:

Cruickshank et al., 2017, Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin., Leukemia

Alternate Names:

D00FHR TTD Drug ID

Alternate Names:

MOCETINOSTAT GuideToPharmacology Ligand Name